FDA Adverse Event Reports on Statin-Associated Rhabdomyolysis
Tóm tắt
To determine the number of cases of statin-associated rhabdomyolysis reported to the Food and Drug Administration for 6 statins and to profile the cases.
A retrospective analysis of all domestic and foreign reports of statin-associated rhabdomyolysis between November 1997 and March 2000 was conducted. Outcome measures included the total number of reports (initial plus follow-up), the number of unique cases, age, gender, percentages of report codes and role codes, and frequencies of concomitant interacting drugs that may have precipitated rhabdomyolysis, outcomes codes, and report source codes.
There were 871 reports of statin-associated rhabdomyolysis in the 29-month time frame examined, representing 601 cases. The following number of cases were associated with each of the individual statins: simvastatin, 215 (35.8%); cerivastatin, 192 (31.9%); atorvastatin, 73 (12.2%); pravastatin, 71 (11.8%); lovastatin, 40 (6.7%); and fluvastatin, 10 (1.7%). Drugs that may have interacted with the statins were present in the following number of cases: mibefradil (n = 99), fibrates (n = 80), cyclosporine (n = 51), macrolide antibiotics (n = 42), warfarin (n = 33), digoxin (n = 26), and azole antifungals (n = 12). The reports of 62.1% of cases were classified as expedited. Statins were designated as the primary suspect in 72.0% of the cases. Death was listed as the outcome in 38 cases. The majority of reports (n = 556) were from health professionals.
Compared with the other statins, simvastatin and cerivastatin were implicated in a relatively higher number of reports. Because of the various limitations of a spontaneous reporting-system database, caution is urged when interpreting the relative number of cases reported.
Từ khóa
Tài liệu tham khảo
Goldman SA, 1995, MedWatch continuing education article. Clinical therapeutics and the recognition of drug-induced disease
MedWatch continuing education article. The clinical impact of adverse event reporting. Staff College, Center for Drug Evaluation and Research, Food and Drug Administration, October 1996. Available from: URL: http://www.fda.gov/medwatch/articles/med.pdf.
Burke LB, 1998, Pharmacoepidemiology: An introduction, 3, 213
FDA talk paper. June 8, 1998. Roche Laboratories announces withdrawal of Posicor from the market [cited 2001 Sep 20]. Available from: URL: http://www.fda.gov/bbs/topics/ANSWERS/ANS00876.html.
FDA talk paper. February 27, 1998. Seldane and generic terfenadine withdrawn from market [cited 2001 Sep 20]. Available from: URL: http://www.fda.gov/bbs/topics/ANSWERS/ANS00853.html.
FDA talk paper. June 21, 1999. Janssen Pharmaceutica announces the withdrawal of Hismanal from the market [cited 2001 Sep 20]. Available from: URL: http://www.fda.gov/bbs/topics/ANSWERS/ANS00961.html.
FDA talk paper. March 23, 2000. Janssen Pharmaceutica stops marketing cisapride in the US [cited 2001 Sep 203. Available from: URL: http://www.fda.gov/bbs/topics/ANSWERS/ANS01007.html.
FDA talk paper. August 8, 2001. Bayer voluntarily withdraws Baycol [cited 2001 Sep 20]. Available from: URL: http://www.fda.gov/bbs/topics/ANSWERS/2001/ANS01095.html.
Scandinavian Simvastatin Survival Study Group, 1994, Lancet, 344, 1383
Illingworth DR, 1994, Clin Ther, 16, 366
Herman R, 1999, Can Med Assoc J, 161, 1281
Dayer-Berenson L, 1994, ANNA J, 21, 15
Prescription drug expenditures in 2000: the upward trend continues. A report by the National Institute for Health Care Management Research and Educational Foundation. May 2001 [cited 2001 Sep 20]. Available from: URL: http://www.nihcm.org.
Sweetman S, 2001, Martindale: the complete drug reference
Weber JCP, 1984, Advances in inflammation research. Vol 6, 1